Edesa Biotech, Inc. 8-K

What Happened

• On June 5, 2026 Edesa Biotech, Inc. (EDSA) announced exploratory analyses for paridiprubart (an anti‑TLR4 monoclonal antibody) in hospitalized patients with acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS). The data were presented at the 63rd European Renal Association (ERA) Congress in Glasgow.
• The combined AKI cohort included 101 patients pooled from the Phase 3 intent‑to‑treat population and earlier Phase 2 data. Using multivariate logistic‑regression adjustments (per the Phase 3 analysis plan), paridiprubart plus standard of care reduced adjusted 28‑day mortality to 33% vs 49% with placebo — a 32% relative risk reduction (nominal p<0.005). The MAKE30 composite (death, new renal replacement therapy, or persistent renal dysfunction at 30 days) fell to 41% vs 53% — a 23% relative reduction (nominal p<0.005). Safety in the AKI subgroup was consistent with prior studies (~400 patients treated), with no meaningful differences in adverse events or infections vs placebo.

Key Details

• Filing date / presentation: June 5, 2026, presented at ERA Congress (Glasgow).
• AKI cohort size: 101 patients (pooled Phase 2 + Phase 3 populations).
• 28‑day mortality: adjusted 33% with paridiprubart vs 49% with placebo (32% relative reduction; nominal p<0.005).
• MAKE30: 41% with paridiprubart vs 53% with placebo (23% relative reduction; nominal p<0.005).
• Patient severity: ~90% had moderate‑to‑severe ARDS; ~50% required invasive ventilation or ECMO; mean age ~58.
• Analysis type & limits: exploratory, not prespecified; results use multivariate logistic regression; nominal p‑values not adjusted for multiplicity; confirmatory trials required.

Why It Matters

• These exploratory results suggest paridiprubart may reduce mortality and kidney‑related complications in a high‑risk subgroup (AKI with ARDS), a population with few targeted treatment options. For investors, the findings may support continued development and potential future trials focused on AKI, but the company emphasizes these are hypothesis‑generating exploratory analyses and not definitive evidence of efficacy. Regulatory or commercial implications depend on confirmatory studies.